HIMS — Hims & Hers Health, Inc.
Is HIMS overbought or oversold? Here is the current MarketMoodz read.
Hims & Hers Health, Inc. (HIMS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $18.56. The rating moved from Oversold to Neutral on November 12, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$18.56
- Last changeMoved from Oversold to Neutral on November 12, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
AI analysis
Hims & Hers Health, Inc. exhibits stable recurring revenue characteristics and a strong direct-to-consumer brand in a large addressable market, but near-term upside is balanced by competitive intensity, sensitivity to customer acquisition and churn dynamics, and limited fresh catalysts in the observed market window. Margin improvement from scale is plausible, yet outcomes depend on execution, marketing efficiency, and managing regulatory/reimbursement shifts. Given mixed visibility on financials and market flows favoring large-cap defensive healthcare, performance near the current price is the most likely short-term scenario with downside risk if growth or retention weakens.
Key factors
- Recurring-revenue subscription model with diversified DTC product portfolio (telehealth, wellness, OTC and Rx services) supports steady revenue cadence
- Brand recognition and direct-to-consumer distribution lower customer acquisition friction versus newer entrants
- Large addressable market in consumer health and telemedicine with secular tailwinds (convenience, digital care adoption)
- Margin expansion potential from scale, lower marketing spend per user and cross-sell of higher-margin services
- Limited publicly-available near-term catalysts in the provided window; broader market preference for large-cap pharma defensives may temper sector flows into small/mid consumer health names
- Balance sheet and cash-flow trends unclear from the provided data window; historical mixed profitability suggests sensitivity to funding/earnings execution
Risks
- Competitive pressure from other telehealth platforms, retail health players, and larger healthcare incumbents expanding into DTC/multi-channel care
- Customer acquisition cost volatility and subscription churn that could compress revenue growth and margin assumptions
- Regulatory and reimbursement changes for telemedicine and prescription delivery could increase operating complexity or costs
- Macroeconomic sensitivity: discretionary consumer spend on wellness products may fall in a tighter economic environment
- Execution risk around international expansion, product launches, or successful cross-selling of higher-margin offerings
- Limited social/research signal in the provided window increases short-term investor uncertainty and potential for sentiment-driven price swings
Latest MarketMoodz coverage
- Hims & Hers tumbles 16% on Q1 loss, weak full-year guidance2026-05-12
- Hims & Hers, GitLab Drive After-Hours Moves Amid Guidance, Restructuring2026-05-11
- Amazon Debuts GLP-1 Weight-Loss Program via One Medical2026-04-21
- Allbirds, Hims & Hers, Microsoft, Xanadu, Tesla: Stocks on Investors' Radar2026-04-16
- Novo Nordisk launches multi-month Wegovy subscriptions2026-03-31
See today's live rating, score and targets
Members see the live hourly rating for HIMS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.